end stage liver disease

Summary

Summary: Final stage of a liver disease when the liver failure is irreversible and LIVER TRANSPLANTATION is needed.

Top Publications

  1. Chen Y, Wang B, Li Y. [Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016]. Zhonghua Gan Zang Bing Za Zhi. 2017;25:181-186 pubmed publisher
    ..4??????????????????????. ..
  2. Yi Z, Mayorga M, Orman E, Wheeler S, Hayashi P, Barritt A. Trends in Characteristics of Patients Listed for Liver Transplantation Will Lead to Higher Rates of Waitlist Removal Due to Clinical Deterioration. Transplantation. 2017;101:2368-2374 pubmed publisher
    ..There will continue to be significant heterogeneity among transplant regions where some patients will be more likely to drop out of the waitlist than receive a transplant. ..
  3. Schlegel V, Treuner Kaueroff T, Seehofer D, Berg T, Becker S, Ceglarek U, et al. Low PCSK9 levels are correlated with mortality in patients with end-stage liver disease. PLoS ONE. 2017;12:e0181540 pubmed publisher
    ..The mean PCSK9 levels in the study population were much lower than those found in normal or healthy populations. Further studies are required to acquire a more detailed understanding of the role of PCSK9 in liver-related mortality. ..
  4. Ding N, Liddle C, Evans R, Downes M. Hepatic actions of vitamin D receptor ligands: a sunshine option for chronic liver disease?. Expert Rev Clin Pharmacol. 2013;6:597-9 pubmed publisher
  5. Kong L, Li M, Li L, Jiang L, Yang J, Yan L. Splenectomy before adult liver transplantation: a retrospective study. BMC Surg. 2017;17:44 pubmed publisher
    ..Moreover, pre-transplantation splenectomy is very effective for the prevention of thrombocytopenia after LT. Pre-transplantation splenectomy is recommended in cases with risky PHT patients without appropriate source of liver for LT. ..
  6. Kelly S, Campbell T, Hillman L, Said A, Lucey M, Agarwal P. The Utilization of Palliative Care Services in Patients with Cirrhosis who have been Denied Liver Transplantation: A Single Center Retrospective Review. Ann Hepatol. 2017;16:395-401 pubmed publisher
    ..Without consultation, aggressive interventions continued until hours before death. We propose that ESLD patients could benefit from PC consultation at time of LT evaluation or based on MELD scores. ..
  7. Fung J, Wong T, Chok K, Chan A, Sin S, Cheung T, et al. Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. Transplantation. 2017;101:2391-2398 pubmed publisher
    ..The long-term outcome was excellent, with survival of 87% at 12 years after transplantation, without any mortality related to HBV reactivation. ..
  8. Lazaridis K, Larusso N. Primary Sclerosing Cholangitis. N Engl J Med. 2016;375:1161-70 pubmed publisher
  9. Lai J, Covinsky K, Dodge J, Boscardin W, Segev D, Roberts J, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology. 2017;66:564-574 pubmed publisher
    ..Hepatology 2017;66:564-574). ..

More Information

Publications46

  1. Li G, Mu X, Huang X, Qian X, Qin J, Tan Z, et al. Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases. Medicine (Baltimore). 2017;96:e7295 pubmed publisher
    ..The partial liver grafts with hepatic benign tumors are safe for liver transplantation. In addition, prosthetic vascular grafts can be used for hepatic venous outflow reconstruction, especially in right lobe liver transplantation. ..
  2. Hsu E, Shaffer M, Gao L, Sonnenday C, Volk M, Bucuvalas J, et al. Analysis of Liver Offers to Pediatric Candidates on the Transplant Wait List. Gastroenterology. 2017;153:988-995 pubmed publisher
    ..Pediatric prioritization in the allocation and development of improved risk stratification systems is required to reduce wait-list mortality among children. ..
  3. Hansen L, Lyons K, Dieckmann N, Chang M, Hiatt S, Solanki E, et al. Background and design of the symptom burden in end-stage liver disease patient-caregiver dyad study. Res Nurs Health. 2017;40:398-413 pubmed publisher
    ..The study will lay the foundation for future research and innovation in ESLD, end-of-life and palliative care, and caregiving. ..
  4. Townsend S, Newsome P. The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016. Dig Dis. 2017;35:371-376 pubmed publisher
    ..A dedicated multidisciplinary NAFLD clinic facilitates rationalisation of services, improves patient outcomes, and provides access to emerging diagnostics and therapies. ..
  5. Fan Z, EnQiang C, Yao D, LiBo Y, Hong L, Lang B, et al. Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure treated with an artificial liver support system. PLoS ONE. 2017;12:e0175332 pubmed publisher
    ..NLR was an independent predictor of mortality in ALSS patients and may assist physicians in determining treatment options. ..
  6. Roth J, Widmer A, Tschudin Sutter S, Dangel M, Frei R, Battegay M, et al. The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in Staphylococcus aureus bloodstream infection: A single-centre observational study. PLoS ONE. 2017;12:e0175669 pubmed publisher
    ..aureus BSIs. We therefore suggest to prospectively validate the MELD score as part of clinical decision support systems in inpatients with suspected or confirmed BSI. ..
  7. Widodo A, Soelaeman E, Dwinanda N, Narendraswari P, Purnomo B. Chronic liver disease is a risk factor for malnutrition and growth retardation in children. Asia Pac J Clin Nutr. 2017;26:S57-S60 pubmed publisher
    ..05 in all cases). Early diagnosis of malnutrition should encourage nutritional support, delay illness progression and increase survival in children with chronic liver disease. ..
  8. Turri J, Decimoni T, Ferreira L, Diniz M, Haddad L, Campolina A. Higher MELD score increases the overall cost on the waiting list for liver transplantation: a micro-costing analysis based study. Arq Gastroenterol. 2017;54:238-245 pubmed publisher
    ..The longer the waiting time, the higher the total cost on list, causing greater impact on health systems. ..
  9. Jalan R, Yurdaydin C, Bajaj J, Acharya S, Arroyo V, Lin H, et al. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4-10 pubmed publisher
  10. Farkas S, Hackl C, Schlitt H. Overview of the indications and contraindications for liver transplantation. Cold Spring Harb Perspect Med. 2014;4: pubmed publisher
    ..Because patients after liver transplantation need lifelong aftercare, it is important for primary care clinicians to understand the basic medical problems and risks. ..
  11. Radhakrishnan K, Chi A, Quan D, Roberts J, Terrault N. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Transplantation. 2017;101:2079-2082 pubmed publisher
  12. Guaraldi G, Dolci G, Zona S, Tarantino G, Serra V, Ballarin R, et al. A frailty index predicts post-liver transplant morbidity and mortality in HIV-positive patients. AIDS Res Ther. 2017;14:37 pubmed publisher
    ..01). We validated FI as a valuable health measure in HIV transplant. In particular, we found a relevant correlation between FI strata at baseline and mortality and a statistically significant correlation between, ?FI and survival rate. ..
  13. Dumitrescu G, Januszkiewicz A, Agren A, Magnusson M, Wahlin S, Wernerman J. Thromboelastometry: Relation to the severity of liver cirrhosis in patients considered for liver transplantation. Medicine (Baltimore). 2017;96:e7101 pubmed publisher
    ..Standard ROTEM cannot discriminate the stage of chronic liver disease in patients with severe chronic liver disease. ..
  14. Santivasi W, Strand J, Mueller P, Beckman T. The Organ Transplant Imperative. Mayo Clin Proc. 2017;92:940-946 pubmed publisher
  15. Lucey M, Terrault N, Ojo L, Hay J, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3-26 pubmed publisher
  16. Fernández Carrillo C, Lens S, Llop E, Pascasio J, Crespo J, Arenas J, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology. 2017;65:1810-1822 pubmed publisher
    ..In this setting, a MELD score ?18 may help clinicians to identify those patients with a higher risk of complications and to individualize treatment decisions. (Hepatology 2017;65:1810-1822). ..
  17. Wadkin J, Patten D, Kamarajah S, Shepherd E, Novitskaya V, Berditchevski F, et al. CD151 supports VCAM-1-mediated lymphocyte adhesion to liver endothelium and is upregulated in chronic liver disease and hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol. 2017;313:G138-G149 pubmed publisher
    ..These regulatory and functional studies identify CD151 as a potential therapeutic target to treat liver fibrosis and HCC. ..
  18. Akdur A, Kirnap M, Ayvazoğlu Soy E, Ozcay F, Moray G, Arslan G, et al. Unusual Indications for a Liver Transplant: A Single-Center Experience. Exp Clin Transplant. 2017;15:128-132 pubmed
    ..Liver transplant effectively treats the underlying defect and the complications of portal hypertension, or risk of malignancy for those disorders, in which the liver is affected. ..
  19. Salama H, Zekri A, Medhat E, Al Alim S, Ahmed O, Bahnassy A, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther. 2014;5:70 pubmed publisher
    ..ClinicalTrials.gov NCT01729221. Registered 17 November 2012. ..
  20. Jiménez J, Carrillo Pérez D, Rosado Canto R, García Juárez I, Torre A, Kershenobich D, et al. Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach. Dig Dis Sci. 2017;62:1855-1871 pubmed publisher
    ..Because most electrolyte and acid-base disturbances are managed in terms of their underlying trigger factors, a systematic physiopathological approach to their diagnosis and treatment is required. ..
  21. Sun K, Hong F, Wang Y, Agopian V, Yan M, Busuttil R, et al. Venovenous Bypass Is Associated With a Lower Incidence of Acute Kidney Injury After Liver Transplantation in Patients With Compromised Pretransplant Renal Function. Anesth Analg. 2017;125:1463-1470 pubmed publisher
    ..Further studies to assess the role of intraoperative VVB in posttransplant AKI are warranted. ..
  22. . EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-485 pubmed publisher
  23. Spengler E, O Leary J, Te H, Rogal S, Pillai A, Al Osaimi A, et al. Liver Transplantation in the Obese Cirrhotic Patient. Transplantation. 2017;101:2288-2296 pubmed publisher
    ..In this review, we examine current practices in the obese liver transplant population, offer recommendations based on the currently available data, and highlight areas where additional research is needed. ..
  24. Murad H, Gazzaz Z, Ali S, Ibraheem M. Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. Braz J Med Biol Res. 2017;50:e6665 pubmed publisher
    ..Improved motor dysfunction by candesartan could be attributed to better brain penetration and slower "off-rate" from angiotensin-II receptors. Clinical trials are recommended. ..
  25. Cholankeril G, Wong R, Hu M, Perumpail R, Yoo E, Puri P, et al. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci. 2017;62:2915-2922 pubmed publisher
    ..75; 95% CI 0.71-0.79, P < .001). Currently, NASH is the most rapidly growing indication for LT in the US. Despite resurgence in ALD, NASH remains the second leading indication for LT. ..
  26. Wei Q, Nemdharry R, Zhuang R, Li J, Ling Q, Wu J, et al. A good prognostic predictor for liver transplantation recipients with benign end-stage liver cirrhosis. Hepatobiliary Pancreat Dis Int. 2017;16:164-168 pubmed
    ..05). PMPM score is a simple and effective tool to predict short-term mortality after liver transplantation in patients with benign liver diseases, and an indicator for prompt salvaging treatment as well. ..
  27. Roth J, Chrobak C, Schädelin S, Hug B. MELD score as a predictor of mortality, length of hospital stay, and disease burden: A single-center retrospective study in 39,323 inpatients. Medicine (Baltimore). 2017;96:e7155 pubmed publisher
    ..We suggest to prospectively validate the MELD score in inpatients as part of clinical decision support systems. ..
  28. Pustavoitau A, Lesley M, Ariyo P, Latif A, Villamayor A, Frank S, et al. Predictive Modeling of Massive Transfusion Requirements During Liver Transplantation and Its Potential to Reduce Utilization of Blood Bank Resources. Anesth Analg. 2017;124:1644-1652 pubmed publisher
    ..Ongoing evaluation of model accuracy and transfusion practices is required to ensure continuing performance of the predictive model. ..
  29. Tapper E, Afdhal N, Curry M. Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation. 2017;101:933-937 pubmed publisher
    ..Fortunately, guidance for navigating these competing concerns can be obtained from cost-effectiveness analyses. Herein, we review the available data on this approach to HCV therapy before or after liver transplant. ..
  30. Rendón J, Cortés Mancera F, Restrepo Gutiérrez J, Hoyos S, Navas M. Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia. PLoS ONE. 2017;12:e0180447 pubmed publisher
    ..The integration events (5q14.1, 16p13 and 20q12) described in this study have not been previously reported. Further studies are required to validate the role of mutations and integration events in OBI pathogenesis. ..
  31. Perazzoli M, Perondi C, Baratto C, Winter E, Creczynski Pasa T, Locatelli C. Gallic Acid and Dodecyl Gallate Prevents Carbon Tetrachloride-Induced Acute and Chronic Hepatotoxicity by Enhancing Hepatic Antioxidant Status and Increasing p53 Expression. Biol Pharm Bull. 2017;40:425-434 pubmed publisher
    ..Thus, these results suggest that GA and DGA has the potential to prevent liver damages as the case of fibrosis condition. ..
  32. Rossle M. Root Cause Analysis: Can It Improve Outcome after Transjugular Intrahepatic Portosystemic Shunt Creation?. J Vasc Interv Radiol. 2015;26:1453-4; quiz 1455 pubmed publisher
  33. Mosna L, Moon J, Hernandez F, Hodgkinson P, Fan J, Selvaggi G, et al. Use of the subcutaneous route and polytetrafluoroethylene grafts for arterial revascularization in liver transplantation. Liver Transpl. 2012;18:499-500 pubmed publisher
  34. Dionigi E, Garcovich M, Borzio M, Leandro G, Majumdar A, Tsami A, et al. Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. Am J Gastroenterol. 2017;112:588-596 pubmed publisher
    ..67). Infection most likely represents a distinct prognostic stage of cirrhosis, which affects survival irrespective of disease severity, even after recovery from the infective episode. ..
  35. Krawczyk M, Grąt M, Grat K, Wronka K, Krasnodębski M, Stypułkowski J, et al. Evolution Of The Results Of 1500 Liver Transplantations Performed In The Department Of General, Transplant And Liver Surgery Medical University Of Warsaw. Pol Przegl Chir. 2015;87:221-30 pubmed publisher
  36. Baron Stefaniak J, Götz V, Allhutter A, Schiefer J, Hamp T, Faybik P, et al. Patients Undergoing Orthotopic Liver Transplantation Require Lower Concentrations of the Volatile Anesthetic Sevoflurane. Anesth Analg. 2017;125:783-789 pubmed publisher
    ..However, as we did not measure propofol concentrations at the time of skin incision, the difference in MAC should be interpreted with caution given that residual propofol may have been present at the time of skin incision. ..
  37. Cheng X, Stedman M, Chertow G, Kim W, Tan J. Utility in Treating Kidney Failure in End-Stage Liver Disease With Simultaneous Liver-Kidney Transplantation. Transplantation. 2017;101:1111-1119 pubmed publisher
    ..These data provide a basis against which benefits derived from urgency-based allocation can be measured. ..